Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „zanubrutinib“
Suchtreffer
Begriffe & Kennungen
Brukinsa · 4.5 · Zanubrutinib is primarily metabolized by cytochrome P450 enzyme 3A (CYP3A).
Eintrag öffnenBrukinsa · 4.5 · Zanubrutinib is primarily metabolized by cytochrome P450 enzyme 3A (CYP3A).
Eintrag öffnenBrukinsa · 4.8 · 34 Zanubrutinib in combination with obinutuzumab The most commonly occurring adverse reactions (≥20%) of zanub
Eintrag öffnenBrukinsa · 4.8 · 36 Table 4: Adverse reactions of zanubrutinib in combination with obinutuzumab reported in clinical study BGB-
Eintrag öffnenBrukinsa · 4.8 · 8 The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib in combination with obinutuzumab w
Eintrag öffnenBrukinsa · 4.8 · 9 Table 3: Adverse reactions of zanubrutinib monotherapy reported in clinical studies in patients with B-cell
Eintrag öffnenBrukinsa · 4.8 · Of the 143 patients treated with zanubrutinib in combination with obinutuzumab, 4.9% of patients discontinued
Eintrag öffnenBrukinsa · 4.8 · Of the 143 patients treated with zanubrutinib in combination with obinutuzumab, 4.9% of patients discontinued
Eintrag öffnenBrukinsa · 4.8 · Of the 1550 patients treated with zanubrutinib, 4.8% of patients discontinued treatment due to adverse reactio
Eintrag öffnenBrukinsa · 4.8 · Of the 1550 patients treated with zanubrutinib, 4.8% of patients discontinued treatment due to adverse reactio
Eintrag öffnenBrukinsa · 4.8 · Table 3: Adverse reactions of zanubrutinib monotherapy reported in clinical studies in patients with B-cell ma
Eintrag öffnenBrukinsa · 4.8 · Table 4: Adverse reactions of zanubrutinib in combination with obinutuzumab reported in clinical study BGB-311
Eintrag öffnenBrukinsa · 4.8 · The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib in combination with obinutuzumab wer
Eintrag öffnenBrukinsa · 4.8 · The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib monotherapy were neutropenia§ (21%),
Eintrag öffnenBrukinsa · 4.8 · The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib monotherapy were neutropenia§ (21%),
Eintrag öffnenBrukinsa · 4.8 · The most commonly occurring adverse reactions (≥20%) of zanubrutinib monotherapy were upper respiratory tract
Eintrag öffnenBrukinsa · 4.8 · The most commonly occurring adverse reactions (≥20%) of zanubrutinib monotherapy were upper respiratory tract
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib in combination with obinutuzumab is based on ROSEWOOD study data from 143 p
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib in combination with obinutuzumab is based on ROSEWOOD study data from 143 p
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib monotherapy is based on pooled data from 1 550 patients with B- cell malign
Eintrag öffnen